COMPASS THERAPEUTICS ($CMPX) posted quarterly earnings results on Monday, August 11th. The company reported earnings of -$0.14 per share, missing estimates of -$0.13 by $0.01. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $CMPX stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
COMPASS THERAPEUTICS Insider Trading Activity
COMPASS THERAPEUTICS insiders have traded $CMPX stock on the open market 5 times in the past 6 months. Of those trades, 3 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $CMPX stock by insiders over the last 6 months:
- ADVISORS LLC ORBIMED sold 3,571,428 shares for an estimated $5,678,570
- CARL L GORDON sold 3,571,428 shares for an estimated $5,678,570
- JONATHAN ANDERMAN (Gen Counsel & Corporate Sec) purchased 20,000 shares for an estimated $30,800
- NEIL LERNER (CHIEF ACCOUNTING OFFICER) purchased 20,000 shares for an estimated $28,400
- THOMAS J. SCHUETZ (CHIEF EXECUTIVE OFFICER) purchased 10,000 shares for an estimated $21,100
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
COMPASS THERAPEUTICS Hedge Fund Activity
We have seen 48 institutional investors add shares of COMPASS THERAPEUTICS stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- TANG CAPITAL MANAGEMENT LLC added 5,152,632 shares (+87.3%) to their portfolio in Q1 2025, for an estimated $9,790,000
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 2,019,810 shares (-33.7%) from their portfolio in Q1 2025, for an estimated $3,837,639
- JPMORGAN CHASE & CO added 1,913,152 shares (+702.5%) to their portfolio in Q1 2025, for an estimated $3,634,988
- BAKER BROS. ADVISORS LP removed 1,010,132 shares (-64.9%) from their portfolio in Q1 2025, for an estimated $1,919,250
- SILVERARC CAPITAL MANAGEMENT, LLC added 874,869 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,662,251
- ROCK SPRINGS CAPITAL MANAGEMENT LP removed 816,620 shares (-14.1%) from their portfolio in Q1 2025, for an estimated $1,551,578
- MACQUARIE GROUP LTD added 681,544 shares (+inf%) to their portfolio in Q1 2025, for an estimated $1,294,933
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
COMPASS THERAPEUTICS Analyst Ratings
Wall Street analysts have issued reports on $CMPX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Raymond James issued a "Outperform" rating on 07/01/2025
- Guggenheim issued a "Buy" rating on 05/09/2025
- D. Boral Capital issued a "Buy" rating on 04/28/2025
- HC Wainwright & Co. issued a "Buy" rating on 04/21/2025
- Leerink Partners issued a "Outperform" rating on 04/02/2025
- Piper Sandler issued a "Overweight" rating on 02/19/2025
To track analyst ratings and price targets for COMPASS THERAPEUTICS, check out Quiver Quantitative's $CMPX forecast page.
COMPASS THERAPEUTICS Price Targets
Multiple analysts have issued price targets for $CMPX recently. We have seen 6 analysts offer price targets for $CMPX in the last 6 months, with a median target of $11.0.
Here are some recent targets:
- Sean McCutcheon from Raymond James set a target price of $9.0 on 07/01/2025
- Michael Schmidt from Guggenheim set a target price of $10.0 on 05/09/2025
- Jason Kolbert from D. Boral Capital set a target price of $32.0 on 04/28/2025
- Joseph Pantginis from HC Wainwright & Co. set a target price of $24.0 on 04/21/2025
- Andrew Berens from Leerink Partners set a target price of $6.0 on 04/02/2025
- Biren Amin from Piper Sandler set a target price of $12.0 on 02/19/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
